Jun Tang

Jining Traditional Chinese Medicine Hospital — China

Immunology and Microbiology · Life Sciences

35h-index5.5kcitations71works3.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Atherosclerosis and Cardiovascular Diseases(13), Nanoparticle-Based Drug Delivery(12), Nanoplatforms for cancer theranostics(10), CAR-T cell therapy research(10), Cancer Immunotherapy and Biomarkers(8)

Publications71 total

P1.11.13 A Phase II Study of Camrelizumab Plus Docetaxol in Advanced NCSLC Pre-Treated With Immune Checkpoint Inhibitors and Chemotherapy
Journal of Thoracic Oncology·2025
Potential role of coagulation markers in early detection of bone metastasis in gastric cancer: A critical review
World Journal of Gastrointestinal Oncology·2025Open Access
A High Immune-Related Index with the Suppression of cGAS-STING Pathway is a Key Determinant to Herceptin Resistance in HER2+ Breast Cancer
International Journal of Biological Sciences·2024· 11 citedOpen Access
Development and validation of a nomogram in survival prediction among advanced breast cancer patients
Annals of Translational Medicine·2020· 4 citedOpen Access
1108P Real world (RW) sequencing outcomes with immunotherapy and targeted therapy (TT) in BRAF+ metastatic melanoma (The NOBLE study series)
Annals of Oncology·2020· 1 citedOpen Access
Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)
Clinical Cancer Research·2020· 9 citedOpen Access
Multimodality labeling strategies for the investigation of nanocrystalline cellulose biodistribution in a mouse model of breast cancer
Nuclear Medicine and Biology·2019· 17 citedOpen Access
Trends in clinical development for PD-1/PD-L1 inhibitors
Nature Reviews Drug Discovery·2019· 214 cited
Immuno-oncology drug development goes global
Nature Reviews Drug Discovery·2019· 259 cited
Imaging-assisted nanoimmunotherapy for atherosclerosis in multiple species
Science Translational Medicine·2019· 69 citedOpen Access
The global pipeline of cell therapies for cancer
Nature Reviews Drug Discovery·2019· 87 cited
Immunotherapy and targeted therapy combinations in metastatic breast cancer
The Lancet Oncology·2019· 456 cited
Abstract A019: Longitudinal analysis of the landscape of cancer trials testing anti-PD-1/L1 monoclonal antibodies
Cancer Immunology Research·2019
Expression, Function and Bioinformatic Analysis of Nicotinamide Phosphoribosyl Transferase in Colon Cancer
SHILAP Revista de lepidopterología·2018Open Access
The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
Nature Reviews Drug Discovery·2018· 368 cited
Erratum: Trends in the global immuno-oncology landscape
Nature Reviews Drug Discovery·2018· 42 citedOpen Access
Trends in the global immuno-oncology landscape
Nature Reviews Drug Discovery·2018· 150 cited
Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis
JACC. Cardiovascular imaging·2018· 95 citedOpen Access
Author Correction: Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates
Nature Biomedical Engineering·2018· 2 citedOpen Access
The global landscape of cancer cell therapy
Nature Reviews Drug Discovery·2018· 72 cited
page 1 of 4Next →

Frequent Co-authors

Willem J. M. Mulder(28), Zahi A. Fayad(21), Thomas Reiner(18), François Fay(15), Carlos Pérez‐Medina(15), Edward A. Fisher(13), Yiming Zhao(12), Claudia Calcagno(11), Brenda L. Sánchez-Gaytán(11), Vanessa M. Hubbard-Lucey(9), Raphaël Duivenvoorden(8), Matthias Nahrendorf(8), Mark E. Lobatto(7), Samantha Baxter(7), Erik S.G. Stroes(6), Filip K. Świrski(6), Max L. Senders(6), Amr Alaarg(6), Jason S. Lewis(6), David P. Cormode(5)